Daiichi Sankyo
AstraZeneca to Discuss Neoadjuvant Enhertu Regimen With Regulators Following Early Data Readout
Patients on Enhertu followed by a chemotherapy and dual anti-HER2 regimen fared better than those on standard therapy.
EC Approves AstraZeneca, Daiichi Sankyo's Enhertu in HER2-low, HER2-Ultralow Breast Cancer
The EC based its decision on data from the DESTINY-Breast06 trial, which included patients whose tumors had very low levels of HER2 expression.
AstraZeneca, Daiichi Sankyo Begin First-Line Trial of Enhertu, Keytruda Combo in Gastric Cancer
The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.
CHMP Recommends Approval of AstraZeneca, Daiichi Sankyo's Enhertu in HER2-Ultralow Breast Cancer
Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.
FDA Accepts Boehringer Ingelheim's New Drug Application for HER2-Targeted Therapy in NSCLC
In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.